NCT01247324
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with multiple sclerosis (MS), confirmed using the 2010 McDonald criteria
- You have had at least 2 MS attacks (relapses) in the last 2 years before screening, OR at least 1 attack before that period — but not within the last 30 days before screening
- Your MS symptoms have been stable for at least 30 days before both the screening and baseline appointments
- Your level of disability falls within a specific range on a standard MS disability scale (called the EDSS, scored 0 to 5.5) (confirm with trial site)
Who may not be able to join:
- You have primary progressive MS (the type that worsens steadily from the start without clear relapses)
- You have had MS for more than 10 years and have very little disability (EDSS score of 2.0 or below) at screening
- You are unable to have an MRI scan for any reason
- You have another neurological condition that could look similar to MS
- You are pregnant or breastfeeding
- You need long-term steroid or immune-suppressing medication during the study period
- You have a history of, or currently have, a condition that weakens your immune system
- You have had a severe allergic or life-threatening allergic reaction to certain types of antibody-based medicines in the past
- You have an active infection, or a history of serious or long-lasting infections such as hepatitis B or C, HIV, syphilis, or tuberculosis
- You have a history of a serious brain infection called progressive multifocal leukoencephalopathy (PML)
- You are unable to take steroid medicines (by mouth or through a drip) for any reason
- You are unable to use or are not suitable for a medication called Rebif (interferon beta-1a)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.